WallStSmart

Agilent Technologies Inc (A)vsCharles River Laboratories (CRL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 76% more annual revenue ($7.07B vs $4.02B). A leads profitability with a 18.3% profit margin vs -3.6%. CRL appears more attractively valued with a PEG of 0.12. A earns a higher WallStSmart Score of 61/100 (C+).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

CRL

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 3.5Value: 6.7Quality: 4.8
Piotroski: 3/9Altman Z: 1.68
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-318.5%)

Margin of Safety

-318.5%

Fair Value

$30.80

Current Price

$112.98

$82.18 premium

UndervaluedFair: $30.80Overvalued

Intrinsic value data unavailable for CRL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

CRL2 strengths · Avg: 9.0/10
PEG RatioValuation
0.1210/10

Growing faster than its price suggests

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

CRL4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.684/10

Distress zone — elevated risk

Operating MarginProfitability
4.5%3/10

Operating margin of 4.5%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-4.2%2/10

ROE of -4.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : CRL

The strongest argument for CRL centers on PEG Ratio, Price/Book. PEG of 0.12 suggests the stock is reasonably priced for its growth.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : CRL

The primary concerns for CRL are Altman Z-Score, Operating Margin, Piotroski F-Score.

Key Dynamics to Monitor

A profiles as a mature stock while CRL is a turnaround play — different risk/reward profiles.

CRL carries more volatility with a beta of 1.65 — expect wider price swings.

A is growing revenue faster at 7.0% — sustainability is the question.

A generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

A scores higher overall (61/100 vs 41/100), backed by strong 18.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Charles River Laboratories

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Want to dig deeper into these stocks?